SNDX (31) NKTR (33) KARD (61) OPK (39) ⌘ Pro Terminal →

LB Pharmaceuticals Inc (LBRX) — RQD Stock Rating Cockpit

$40.15 +0.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

LB Pharmaceuticals Inc (LBRX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $1.30B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LBRX)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

52.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE72% OF RANGE

L: $14$40.15H: $50

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LBRX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-8.4% ROIC with 42.0% gross margin and -2.72% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

16/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like LBRX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LBRX)

✓Walkthrough of LBRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LBRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +26.62%⚡ TESTING RESISTANCE

2026-10-30O $40.10H $41.24L $39.13C $40.15VOL 429.4K

RES: $40.72SUP: $34.35SMA50: $41.38SMA200: $32.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LBRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LBRX Butterfly Map → + Track LBRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LBRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LBRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LBRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LBRX)

Health Care Rank #543 of 1016 ⚔️ SNDX vs LBRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LBRX vs. SNDX, NKTR, KARD, OPK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LB Pharmaceuticals Inc (LBRX) ranks #543 by composite RQD confidence (43/100, grade D-) and #327 by equity capitalization ($1.30B). Within this direct 5-issuer industry benchmark cohort, LBRX leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with LBRX at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LBRX ACTIVE LB Pharmaceuticals Inc	D-	43/100	—	—	-8.4%	+0.80%	$1.30B	Benchmark Subject
SNDX Syndax Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.19%	$1.26B	/sndx-vs-lbrx →
NKTR Nektar Therapeutics	E	33/100	—	96.0%	-35.0%	+1.63%	$1.34B	/nktr-vs-lbrx →
KARD Kardigan Inc.	C-	61/100	—	—	—	+4.22%	$1.34B	/kard-vs-lbrx →
OPK OPKO Health Inc.	D-	39/100	—	33.9%	-10.2%	+2.47%	$1.24B	/opk-vs-lbrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001691082

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LB Pharmaceuticals Inc (LBRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$25.2M, operating cash flow of -$35.2M, and free cash flow of -$35.3M (+34.5% YoY). On the balance sheet, LBRX closed FY2025 with $312.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$25.2M	-$35.2M	-$35.3M	$312.9M	—
FY2024 (FY)	2024-12-31	$0	-$63.1M	-$53.1M	-$53.8M	$33.5M	—

3. LBRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, LB Pharmaceuticals Inc (NASDAQ: LBRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $40.15 (+0.80% 1D, market cap $1.30B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LBRX ranks #543 in composite RQD confidence.

How does LBRX compare to SNDX and NKTR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LBRX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -8.4%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.26B) and NKTR (Nektar Therapeutics) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.34B). Among the 5-stock peer group, LBRX leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LBRX?

Per LBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001691082), LB Pharmaceuticals Inc generated $0 in revenue, -$25.2M in net income, and -$35.3M in free cash flow against $312.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LBRX trading relative to its 50-day, 200-day, and 52-week technical levels?

LBRX last traded at $40.15 (+0.80% on volume of 400,682 shares), positioning the stock -2.97% below its 50-day simple moving average ($41.38) and +23.27% above its 200-day simple moving average ($32.57). Across its 52-week range of $14.32 to $50.16, LBRX sits at the 72.1% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($35.13 to $45.17).

LBRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LBRX stock right now?

LB Pharmaceuticals Inc (LBRX) currently earns a Roarable Rating of D- (Sell — SELL) with 43/100 RQD Confidence. Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.

What is LBRX's 12-month price target and RQD AI Jury consensus?

LBRX's 12-month base price target is $37.44 (range $29.2 to $52.67), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LBRX RQD Cockpit LBRX 12M Forecast LBRX Earnings & Move LBRX Dividends & DRIP LBRX Insiders & 13F LBRX Whale Options LBRX Profit Sankey LBRX News & Why